A brief cognitive assessment for use with schizophrenia patients in community clinics

Schizophrenia Research

Volumn 71, Issue 2-3, 2004, Pages 273-283

  Velligan, Dawn I ^a   DiCocco, Margaret ^a   Bow Thomas, C Christine ^a   Cadle, Christopher ^a   Glahn, David C ^a   Miller, Alexander L ^a,b   Biggs, Melanie M ^c   Shores Wilson, Kathy ^c   McKenzie, Christine A ^c   Crismon, M Lynn ^d,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b San Antonio State Hospital   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e Texas Dept Mental Hlth Mental R   (United States)

Author keywords

Brief cognitive assessment; Cognitive impairments; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEDATIVE AGENT;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CORRELATION ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PRIORITY JOURNAL; RELIABILITY; SCHIZOPHRENIA; VALIDATION PROCESS;

ADULT; ALGORITHMS; AMBULATORY CARE FACILITIES; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COMMUNITY HEALTH SERVICES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 4944252411     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.02.027     Document Type: Article

References (50)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 1994;American Psychiatric Association, Washington, DC
2. Arvanitis L.A., Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol. Psychiatry. 42(4):1997;233-246
3. Barker S., Barron N., McFarland B., Bigelow D. A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity. Com. Ment. Health J. 30(4):1994;363-383
4. Beasley C.M., Sanger T.M., Satterlee W., Tollefson G., Tran P.V., Hamilton S.H. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124(1-2):1996;159-167
5. Brandt J. The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. Clin. Lab. Neuropsychol. 5:1991;125-142
6. Cohen T.J. Statistical Power Analysis for the Behavioral Sciences. 1988;Lawrence Erlbaum Associates, Hillsdale, NJ
7. Delis D.C., Kramer J.H., Kaplan E., Ober B.A. California Verbal Learning Test-Adult Version Research Edition, manual. 1987;The Psychological Corporation, New York
8. Dombrowski S.B., Kane M., Tuttle N.B., Kincaid W. Functional needs assessment program for chronic psychiatric patients. 1990;Communication Skill Builders, Tucson, AZ
9. Gilbert D.A., Altshuler K.Z., Rago W.V., Shon S.P., Crismon M.L., Toprac M.G., Rush A.J. Texas medication algorithm project-1: definitions, rationale, and methods to develop medication algorithms. J. Clin. Psychiatry. 59:1998;345-351
10. Gold J.M. Brief assessment of cognitive function in schizophrenia. 42nd Annual NCDEU Meeting, Boca Raton, FL. 2002
11. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 16(2):1993;295-312
12. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia: I. Sensitivity, reliability, and validity. Am. J. Psychiatry. 156(12):1999;1944-1950
13. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schultz S.C., Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48
14. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153(3):1996;321-330
15. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26(1):2000;119-136
16. Harvey P.D. Brief assessment of cognitive function in schizophrenia. 42nd Annual NCDEU Meeting, Boca Raton, FL. 2002
17. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry. 158(2):2001;176-184
18. Heaton R.K., Grant I., Matthews C.G. Comprehensive norms for an expanded Halstead-Reitan Battery with a Supplement for the Wechsler Adult Intelligence Scale-Revised (WAISR). 1991;Psychological Assessment Resources, Inc., Lutz, FL
19. Hobart M.P., Goldberg R., Bartko J.J., Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia: II. Convergent/discriminant validity and diagnostic group comparisons. Am. J. Psychiatry. 156(12):1999;1951-1957
20. Keefe R. Brief assessment of cognitive function in schizophrenia. 42nd Annual NCDEU Meeting, Boca Raton, FL. 2002
21. Keefe R.S., et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 68:2004;283-297
22. Lehman, A.F., 1997. Lehman Work and Productive Activity Scale. unpublished manuscript.
23. Lezak M. Neuropsychological Assessment. 1995;Oxford Univ. Press, New York, NY
24. Mahurin R.K. NeuroCog: a self-administered cognitive assessment battery. Paper Presented at the Symposium on Computerized Behavioral Testing, Portland, Oregon. 1995
25. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25(2):1999;233-255
26. Miller A.L., Chiles J.A., Chiles J.K., Crismon M.L., Rush J., Shon S.P. The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms. J. Clin. Psychiatry. 60(10):1999;649-657
27. Mitrushina M.N., Boone K.B., D'Elia L.F. Handbook of Normative Data for Neuropsychological Assessment. 1999;Oxford Univ. Press, New York, NY
28. Mortimer A.M. Cognitive function in schizophrenia - do neuroleptics make a difference? Pharmacol. Biochem. Behav. 56:1996;789-795
29. Purdon S.E., Jones B.D.W., Stip E., Labelle A., Addington D., David S.R., Breier A., Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry. 57(3):2000;249-258
30. Purdon S.E., Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26(2):2001;137-149
31. Randolph C. Repeatable battery for the assessment of neuropsychological status. 1998;Psychological, San Antonio
32. Rush A.J., Crismon M.L., Kashner T.M., Toprac M.G., Carmody T.M., Trivedi M.H., Suppes T., Miller A.L., Biggs M.M., Shores-Wilson K., Witte B., Shon S.P., Rago W.V., Altshuler K.Z. Texas Medication Algorithm Project-Phase III (TMAP III): rationale and design. J. Clin. Psychiatry. 64(4):2003;357-369
33. Saykin A.J., Gur R.E., Gur R.C., Mozley P.D. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry. 48:1991;618-622
34. Selnes O.A., Jacobson L., Machado A.M., Becker J.T., Wesch J., Miller E.N., Visscher B., McArthur J.C. Normative data for a brief neuropsychological screening battery. Percept. Mot. Skills. 73:1991;539-550
35. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18(Suppl. 1):1998;12S-19S
36. Shon S.P., Crismon M.L., Toprac M.G., Trivedi M., Miller A.L., Suppes T., Rush A.J. Mental health care from the public perspective: the Texas Medication Algorithm Project. J. Clin. Psychiatry. 60(Suppl. 3):1999;16-21
37. Shores-Wilson K., Biggs M.M., Miller A.L., Carmody T.M., Chiles J.A., Rush A.J., Crismon M.L., Toprac M.G., Witte B.P., Webster J.C. Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. Int. J. Methods Psychiatr. Res. 11(1):2002;45-53
38. Spreen O., Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 1998;Oxford Univ. Press, New York, NY
39. Tandon R., Harrigan E., Zorn S.H. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J. Serotonin Res. 1997;159-177
40. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154(4):1997;457-465
41. Trenerry M., Crosson B. Stroop Neuropsychological Screening Test Manual. 1989;Psychological Assessment Resources (PAR), Odessa, FL
42. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 25(1):1997;21-31
43. Velligan D.I., Bow-Thomas C.C., Mahurin R.K., Miller A.L., Halgunseth L.C. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia. J. Nerv. Ment. Dis. 188:2000;518-524
44. Velligan D.I., Newcomer J.W., Pultz J., Csernansky J.G., Hoff A.L., Mahurin R.K., Miller A.L. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53:2002;239-248
45. Velligan D.I., Prihoda T.J., Sui D., Ritch J.L., Maples N., Miller A.L. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry. 64(5):2003;524-531
46. Ventura J., Green M.F., Shaner A., Liberman R.P. Training and quality assurance with the brief psychiatric rating scale: 'The Drift Busters'. Int. J. Methods Psychiatr. Res. 3:1993;221-244
47. Wilk C.M., Gold J.M., Bartko J.J., Dickerson F.B., Fenton W.S., Knable M., Randolph C., Buchanan R.W. Test-retest stability of the repeatable battery for the assessment of neuropsychological status of schizophrenia. Am. J. Psychiatry. 159:2002;838-844
48. Wyatt R.J., Hentler I., Leary M.C., Taylor E. An economic evaluation of schizophrenia 1991. Soc. Psychiatry Psychiatr. Epidemiol. 30(5):1995;196-205
49. Yeudall L.T., Fromm D., Reddon J.R., Stefanyk W.O. Normative data stratified by age and sex for 12 neuropsychological tests. J. Clin. Psychol. 43(3):1986;918-946
50. Zgaljardic D.J., Benedict R.H.B. Evaluation of Practice Effects in Language and Spatial Processing Test Performance. Appl. Neuropsychol. 8(4):2001;218-223